BRIEF-Hookipa Pharma Inc - On November 18 Approved Plan to Reduce Workforce By Approximately 80%

Reuters11-21 06:27

Nov 20 (Reuters) - HOOKIPA Pharma Inc :

* HOOKIPA PHARMA INC - ON NOVEMBER 18, CO APPROVED A PLANTO REDUCE WORKFORCE BY APPROXIMATELY 80%

* HOOKIPA PHARMA - RESTRUCTURING PLAN TO BEGIN IN Q4 2024, COMPLETE BY H1 2025

* HOOKIPA PHARMA - TO PAUSE CLINICAL DEVELOPMENT IN ESEBA-VEC PROGRAM

* HOOKIPA PHARMA - EARLY TERMINATION OF HPV16+ TRIAL NOT DUE TO EFFICACY OR SAFETY

* HOOKIPA PHARMA INC: WILL FOCUS PRIMARILY ON PROGRESSING THE PHASE 1-READY HB-700 PROGRAM FOR THE TREATMENT OF KRAS MUTANT CANCERS

Source text: [ Further company coverage:

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485742861?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-21 06:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485742861","market":"us","top_or_hot":-1,"title":"BRIEF-Hookipa Pharma Inc - On November 18 Approved Plan to Reduce Workforce By Approximately 80%","media":"Reuters","content":"<html><body><p>Nov 20 (Reuters) - HOOKIPA Pharma Inc   :</p><p>   * HOOKIPA PHARMA INC - ON NOVEMBER 18, CO APPROVED A PLANTO REDUCE WORKFORCE BY APPROXIMATELY 80%</p><p>   * HOOKIPA PHARMA - RESTRUCTURING PLAN TO BEGIN IN Q4 2024, COMPLETE BY H1 2025</p><p>   * HOOKIPA PHARMA - TO PAUSE CLINICAL DEVELOPMENT IN ESEBA-VEC PROGRAM</p><p>   * HOOKIPA PHARMA - EARLY TERMINATION OF HPV16+ TRIAL NOT DUE TO EFFICACY OR SAFETY</p><p>   * HOOKIPA PHARMA INC: WILL FOCUS PRIMARILY ON PROGRESSING THE PHASE 1-READY HB-700 PROGRAM FOR THE TREATMENT OF KRAS MUTANT CANCERS</p><p>Source text: [ Further company coverage:   </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Hookipa Pharma Inc - On November 18 Approved Plan to Reduce Workforce By Approximately 80%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Hookipa Pharma Inc - On November 18 Approved Plan to Reduce Workforce By Approximately 80%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-21 06:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 20 (Reuters) - HOOKIPA Pharma Inc   :   * HOOKIPA PHARMA INC - ON NOVEMBER 18, CO APPROVED A PLANTO REDUCE WORKFORCE BY APPROXIMATELY 80%   * HOOKIPA PHARMA - RESTRUCTURING PLAN TO BEGIN IN Q4 ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2485742861","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485742861","pubTimestamp":1732141644,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Nov 20  - HOOKIPA Pharma Inc   :   * HOOKIPA PHARMA INC - ON NOVEMBER 18, CO APPROVED A PLANTO REDUCE WORKFORCE BY APPROXIMATELY 80%   * HOOKIPA PHARMA - RESTRUCTURING PLAN TO BEGIN IN Q4 2024, COMPLETE BY H1 2025   * HOOKIPA PHARMA - TO PAUSE CLINICAL DEVELOPMENT IN ESEBA-VEC PROGRAM   * HOOKIPA PHARMA - EARLY TERMINATION OF HPV16+ TRIAL NOT DUE TO EFFICACY OR SAFETY   * HOOKIPA PHARMA INC: WILL FOCUS PRIMARILY ON PROGRESSING THE PHASE 1-READY HB-700 PROGRAM FOR THE TREATMENT OF KRAS MUTANT CANCERSSource text: [ Further company coverage:","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","HOOK":"Hookipa Pharma Inc","BK4505":"高瓴资本持仓"},"translate_title":"简介-Hookipa Pharma Inc-11月18日批准裁员约80%的计划","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HOOK":1},"content_text":"Nov 20 (Reuters) - HOOKIPA Pharma Inc   :   * HOOKIPA PHARMA INC - ON NOVEMBER 18, CO APPROVED A PLANTO REDUCE WORKFORCE BY APPROXIMATELY 80%   * HOOKIPA PHARMA - RESTRUCTURING PLAN TO BEGIN IN Q4 2024, COMPLETE BY H1 2025   * HOOKIPA PHARMA - TO PAUSE CLINICAL DEVELOPMENT IN ESEBA-VEC PROGRAM   * HOOKIPA PHARMA - EARLY TERMINATION OF HPV16+ TRIAL NOT DUE TO EFFICACY OR SAFETY   * HOOKIPA PHARMA INC: WILL FOCUS PRIMARILY ON PROGRESSING THE PHASE 1-READY HB-700 PROGRAM FOR THE TREATMENT OF KRAS MUTANT CANCERSSource text: [ Further company coverage:","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485742861"}